companydata.dkCONTERA PHARMA A/S: Financial statements 2013
CVR: 33062214
CONTERA PHARMA A/S (CVR 33062214) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK -3,423,079 and a net result of DKK -4,726,146 compared with DKK -4,245,465 the year before. Equity amounted to DKK 1,675,540. The solvency ratio was 40.8%.
- Gross Profit
- -3,423,079 kr.
- Profit/Loss
- -4,726,146 kr.
- Equity
- 1,675,540 kr.
- Total Assets
- 4,111,142 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2013 | - | -3.4 mio. | -4.7 mio. | 1.7 mio. | - |
| 2012 | - | -3.7 mio. | -4.2 mio. | 6.4 mio. | - |
Find more companies like CONTERA PHARMA A/S
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2013
As of November 19, 2013, Else Sissel Vorstrup has joined the board of directors of CONTERA PHARMA A/S.
As of November 19, 2013, Joseph Donald deBethizy has joined the board of directors of CONTERA PHARMA A/S.
As of November 19, 2013, John Bondo Hansen has left the board of directors of CONTERA PHARMA A/S.
On November 19, 2013, the company changed its name from CONCIT PHARMA ApS to CONTERA PHARMA ApS.
CONTERA PHARMA A/S has published its annual report for 2012. Gross profit came to DKK -3,689,746, and the net result was DKK -4,245,465.
About CONTERA PHARMA A/S
CONTERA PHARMA A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2010. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CONTERA PHARMA ApS and CONCIT PHARMA ApS. The management consists of Thomas Nikolaj Sager. The company is owned by Bukwang Pharmaceutical Co., Ltd. The company has 1 employee. In 2025, the company reported a gross profit of DKK 20,632,306 and a net result of DKK -4,783,781 compared with DKK -69,213,744 the year before. Equity amounted to DKK 79,471,802.